Skip to search formSkip to main contentSkip to account menu

Zosuquidar

Known as: (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol 
A difluorocyclopropyl quinoline. Zosuquidar binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR… 
National Institutes of Health

Related topics

Related topics

1 relation
zosuquidar trihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
1 PARP INHIBITORS AS P-GLYOPROTEIN SUBSTRATES
The cytotoxicity of PARP inhibitors olaparib, veliparib and CEP-8983 were investigated in two P-glycoprotein overexpressing drug… 
2012
2012
Abstract 779: Prodrug-mediated reversal of multidrug resistance in breast cancer cells
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The P-glycoprotein (P-gp) is a 170 kDa protein… 
2011
2011
Zosuquidar reverses P-glycoprotein-mediated multidrug resistance in patients with liver cancer
Objective To reverse multidrug resistance(MDR) by zosuquidar trihydrochloride(LY335979,zosuquidar.3HC1) in the patients with… 
2010
2010
Group 3999 leukemia : a randomized , placebo-controlled trial of the Eastern outcome of older patients with newly diagnosed acute myeloid Zosuquidar , a novel modulator of P-glycoprotein
Bennett, Jacob M. Rowe, Hillard M. Lazarus, Selina Luger and Martin S. Tallman Larry D. Cripe, Hajime Uno, Elisabeth M. Paietta… 
2006
2006
Zosuquidar for the treatment of cancer, daunorubicin, and cytarabine
The present invention, zosuquidar, using a combination of daunorubicin and cytarabine, provides a method of treating a patient… 
2006
2006
Calicheamicin - treatment of cancer patients using the antibody conjugates in combination with Zosuquidar
The present invention, zosuquidar and calicheamicin - using a combination of antibody complex (e.g. Mylotarg), provides a method…